Eyestem plans to further investigate these promising results in a phase 2 study in India and the US. The company previously announced it had completed the first round of dosing in its trial in August ...

(RTTNews) - Late-stage clinical biopharmaceutical company Sellas Life Sciences Group, Inc. (SLS) Tuesday announced positive survival in Cohort 3 data from the ongoing Phase 2 trial of SLS009 ...

The information and technology gauge Nifty IT index jumped three percent in the opening session on April 8, tracking positive global cues as the risk-off mode ebbed, giving way to a bullish market ...

“The remarkable results from Cohort 3 of the ongoing Phase 2 trial reinforce the potential of SLS009 to transform outcomes for these heavily pretreated AML patients,” said Angelos Stergiou, MD, ScD ...

Credit: Getty Images In a phase 3 clinical trial ... and safety of inebilizumab in adult patients with gMG who tested positive for either acetylcholine receptor (AChR+) or muscle-specific kinase ...

The 25-year-old still has some ways to go before returning to the big leagues, but he is making very positive strides ... Gibson was able to go up-and-down three times and he is nearing a debut ...

Phase 4 saw TV shows folded into the MCU's interconnected ... That will complete the second of the MCU's two Sagas to date, both of which contain three Phases. If this sounds like a lot, we ...

a differentiated protocol that is aligned with the positive subpopulation data and informed by feedback from discussions with the FDA is expected to guide the design of the planned Phase 3 trial.

As a once-daily oral therapy, based on the data from this study, ICP-488 will be “a valuable treatment option for moderate to severe plaque psoriasis” if phase 3 data confirm these findings ...

Following a successful Type B end-of-phase 2 meeting, the FDA has approved the start of a phase 3 trial of linperlisib in peripheral T-cell lymphoma. The FDA has granted clearance to initiate a global ...

provides fundamental findings and compelling evidence that Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive ... (33.3%). Currently, the efficacy of extended adjuvant ...